RT-1972 / Raya Therap - LARVOL DELTA

The Combination Of RT1999 And RT1972 From Preclinical To Clinical Development (ENCALS 2026) - "This study is intended to initially determine safety and tolerability of the combination in persons living with ALS, as well as identify biomarkers for the future development. Conclusion Currently presented preclinical data of the combination, and the previous clinical development of the compounds separately, are the foundation for future early-stage clinical development of this combination of RT1972 and RT1999 for the treatment of ALS."

Preclinical

Raya Therapeutic Announces Oral Presentation and Poster at International Symposium on ALS/MND in Montreal December 6-8 (EIN News) - "Raya Therapeutic Inc...announces the presentation of the Phase 2 ROCK-ALS study data for its lead compound, fasudil (RT1968) for the treatment of Amyotrophic Lateral Sclerosis (ALS) by Dr. Paul Lingor (Principal Investigator) on Friday, December 6th at the 35th International Symposium on ALS/MND in Montreal...The company would also like to announce a poster presentation...entitled: 'The novel combination of 2 clinical-stage molecules demonstrates a beneficial effect in preclinical models of ALS.' Raya is also developing 2 novel small molecules, RT1972 and RT1999, each of which have neuroprotective effects in ALS preclinical models...Raya believes that this is the first presentation of a combination of two new chemical entities across multiple preclinical models of ALS."

P2 data • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders